10th EMIM European Molecular Imaging Meeting
Organiser: ESMI European Society for Molecular Imaging Web: www.emim.eu
Date: 18-20 MARCH 2015
Venue: Kupferbau Tuebingen, Hölderlinstraße 5, 72074 Tübingen, Germany
Abstract categories: Cardiology Imaging Probes, Chemistry & Reporter Genes Imaging Technology, Methodology & Software Immunology/Inflammation Infectious Diseases Oncology Neurology Others
3rd November 2014| Opening of EMIM Abstract Submission
9th December 2014| DEADLINE for EMIM Abstract Submission
Our 60th Annual Meeting Program Co-chairs, Mike Clemenshaw, MD and Lucrecia Pantarotto, CNMT, in cooperation with the Program Committee, have begun developing educational sessions which will include a lot of Cardiac Nuclear Medicine as well as timely updates on General Nuclear Medicine Studies. At our 59th Annual Meeting, we offered nine SAM and we hope to match those numbers for 2015.
46th Annual Spring Educational Conference and Exhibition - MECSNM
Join David Schuster, MD, August 21 at 3 pm ET for a one-hour webinar and learn more about anti-1-amino-3-[18F]fluorocyclobutane-1-carboxylic acid (anti-[18F]FACBC)—a synthetic amino acid PET radiotracer that has shown promise in staging and restaging patients with prostate cancer—the current status of using FACBC, and results of key clinical trials.
SNMMI 2014 Patient Hill Day
This workshop will provide a practical introduction to positron emission tomography (PET) imaging. The basic physics and chemistry of PET will be presented, along with examples of its use in cancer, cardiovascular, and neurological research and patient management. The use of PET for diagnosis, staging, and treatment, in addition to monitoring of treatment will be discussed. Regulatory issues concerning the introduction of new PET imaging agents will be covered.
Our Fall Technologist Meeting is a one-day course designed especially for nuclear medicine technologists. We are only seeking VOICE credit (no other types of CEs). Attendees will gain up to seven VOICE credits for participating in this course.
NANETs/ SNMMI Symposium: Improvements in NET Imaging
Gallium-68-DOTA compounds that target somatostatin receptors have been used with PET to significantly improved the quality of imaging neuroendocrine tumors. Although approved in Europe, this class of agent has only been used in investigational trials under INDs in the US. Expanded efforts are underway to move them towards approval and into clinical practice. Recently, both 68Ga-DOTATOC and 68Ga-DOTATATE (GalioMedix ™) were granted orphan drug status by the FDA for the management of neuroendocrine tumors. These announcements have garnered widespread interest and elevated enthusiasm for using gallium imaging agents, but some issues related to using these agents remain unclear. Join David Dick, PhD, on Thursday, October 23 at 3:00pm ET, as he describes the current trials underway using the three Ga-68 DOTA agents (NOC/TATE/TOC) along with updates on the manufacturing, production and availability of the agents for clinical and/or investigational use.